SpliSense begins Phase IIb SPL84 trial for cystic fibrosis
SpliSense anticipates top-line results in the second half of 2027.
News
Arrowhead reports top-line results in mixed hyperlipidaemia trial
Taiho, Cullinan report improved PFS in Phase III NSCLC trial
First healthy volunteers dosed in Bionyra’s Phase I BYN-001 study
Tyra announces initial data from Phase II SURF302 trial of dabogratinib
BMS reports positive data from Phase II QUINTESSENTIAL study for r/r MM
Rezubio doses first cohort in Phase I trial of inhaled RZ-520
Novartis’ pelacarsen fails to meet primary endpoint in Lp(a)HORIZON trial
